Document:

EX-10.14(i)

 Exhibit 10.14(i) 

FIFTH AMENDMENT TO 

EMPLOYMENT AGREEMENT 

THIS AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”) is made by and between Samuel N. Hazen (the
“Executive”) and HCA Healthcare, Inc., a Delaware corporation (the “Company”), effective as of January 1, 2019. 

WITNESSETH: 

WHEREAS, HCA Inc. previously entered into an Employment Agreement (the “Employment Agreement”) with the
Executive dated November 16, 2006; 
 WHEREAS, on November 22, 2010, the Company completed a corporate
reorganization pursuant to which the Company became the direct parent company of, and successor issuer to, HCA Inc. (the “Corporate Reorganization”); 

WHEREAS, the Company assumed the Employment Agreement in connection with the Corporate Reorganization; 

WHEREAS, the Employment Agreement was previously amended effective February 9, 2011, January 29, 2015,
January 27, 2016 and November 14, 2016; and 
 WHEREAS, the Company and the Executive desire to further
amend the Employment Agreement as provided herein. 
 NOW, THEREFORE, for the reasons set forth above, and other
valid consideration, the receipt of which is hereby acknowledged, the Company and the Executive hereby amend the Employment Agreement as follows: 

1.    Amendments. Section 2(a) of the Employment Agreement is deleted in its entirety and
replaced with the following: 
 “a. During the Employment Term, Executive shall serve as the Chief Executive Officer of
the Company. In such position, Executive shall have such duties, authority and responsibility as shall be determined from time to time by the Board of Directors which duties, authority and responsibility are consistent with those attendant to such
position with the Company with respect to the business of the Company. Executive shall, if requested, also serve as a member of the Board of Directors of any affiliate of the Company, without additional compensation.” 

2.    Certain Definitions. Capitalized terms used in this Amendment not otherwise defined herein
shall have the same meaning as set forth in the Employment Agreement. 
 3.    Effect of
Amendment. Except as modified hereby, the Employment Agreement shall remain unaffected and in full force and effect. 

 4.    Counterparts. This Amendment may be
executed in counterparts, each of which shall be an original but all of which shall constitute but one document. 
 [Signature page
follows] 

  
 2 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement,
intending to be legally bound, as of the date first stated above. 
  

			
	HCA HEALTHCARE, INC.
		
	 By:
	 	 /s/ John M. Steele

	Name:	 	 John M. Steele

	Title:	 	 Senior Vice President and Chief Human Resource Officer

  

	
	 /s/ Samuel N. Hazen

	Samuel N. HazenEX-10.41

 Exhibit 10.41 

Form of HCA Healthcare, Inc. 

Stock Appreciation Rights Agreement 

This STOCK APPRECIATION RIGHTS AGREEMENT (the “Agreement”), dated as of
                             (the “Grant Date”) is made by and between HCA
Healthcare, Inc., a Delaware corporation (together with its Subsidiaries, Successors and other applicable Service Recipients, hereinafter referred to as the “Company”), and the individual whose name is set forth below, who is an
employee of the Company and hereinafter referred to as the “Grantee”. Any capitalized terms herein not otherwise defined in Article I shall have the meaning set forth in the 2006 Stock Incentive Plan for Key Employees of HCA
Holdings, Inc. and its Affiliates, as amended and restated (the “Plan”). 
 WHEREAS, the Company wishes to
carry out the Plan, the terms of which are hereby incorporated by reference and made a part of this Agreement; and 

WHEREAS, the Compensation Committee of the Board of Directors of the Company, including any subcommittee formed pursuant to
Section 3(a) of the Plan, (or, if no such committee is appointed, the Board of Directors of the Company) (the “Committee”) has determined that it would be to the advantage and best interest of the Company and its shareholders
to grant an award of Stock Appreciation Rights (“SARs”) as provided for herein to the Grantee as an incentive for increased efforts during his or her term of office, employment or service with the Company, and has advised the
Company thereof and instructed the undersigned officers to issue said SARs; 
 NOW, THEREFORE, in consideration of the
mutual covenants herein contained and other good and valuable consideration, receipt of which is hereby acknowledged, the parties hereto do hereby agree as follows: 

STOCK APPRECIATION RIGHTS GRANT 
  

			
	 Grantee:
	  	 [Participant Name]

		  	 [Participant Address]

		
	 Aggregate number of SARs granted hereunder:
	  	[SAR Award]
		
	 Base Price of all SARs granted hereunder:
	  	 [Base Price]

		
	 Grant Date of Award (“Grant Date”):
	  	 [Grant Date]

 ARTICLE I 

DEFINITIONS 

Whenever the following terms are used in this Agreement, they shall have the meaning specified below unless the context
clearly indicates to the contrary. 
 Section 1.1.    Cause 

“Cause” shall mean “Cause” as such term may be defined in any employment agreement or change-in-control agreement in effect at the time of termination of employment between the Grantee and the Company or, if there is no such employment or change-in-control agreement, “Cause” shall mean (i) willful and continued failure by Grantee (other than by reason of a Permanent Disability) to perform his or
her material duties with respect to the Company which continues beyond ten (10) business days after a written demand for substantial performance is delivered to Grantee by the Company (the “Cure Period”); (ii) willful or
intentional engaging by Grantee in material misconduct that causes material and demonstrable injury, monetarily or otherwise, to the Company or its Affiliates; (iii) conviction of, or a plea of nolo contendere to, a crime constituting
(x) a felony under the laws of the United States or any state thereof or (y) a misdemeanor for which a sentence of more than six months’ imprisonment is imposed; or (iv) Grantee’s engaging in any action in breach of
restrictive covenants made by Grantee under any agreement containing restrictive covenants (e.g., covenants not to disclose confidential information, to compete with the business of the Company or to solicit the employees thereof to terminate their
employment) or any employment or change-in-control agreement between the Grantee and the Company, which continues beyond the Cure Period (to the extent that, in the
Board’s reasonable judgment, such breach can be cured). 
 Section 1.2.    Good Reason 

“Good Reason” shall mean “Good Reason” as such term may be defined in any employment agreement or change-in-control agreement in effect at the time of termination of employment between the Grantee and the Company, or, if there is no such employment or change-in-control agreement, “Good Reason” shall mean (i) (A) a reduction in Grantee’s base salary (other than a general reduction in base salary that
affects all similarly situated employees (defined as all employees within the same Company pay grade as that of Grantee) in substantially the same proportions that the Board implements in good faith after consultation with the Chief Executive
Officer and Chief Operating Officer of the Company, if any); (B) a reduction in Grantee’s annual incentive compensation opportunity; or (C) the reduction of benefits payable to Grantee under the Company’s Supplemental Executive
Retirement Plan (if Grantee is a participant in such plan), in each case other than any isolated, insubstantial and 

  
 2 

 
inadvertent failure by the Company that is not in bad faith and is cured within ten (10) business days after Grantee gives the Company written notice of such event; provided that the
events described in (i)(A) or (i)(B) above will not be deemed to give rise to Good Reason if employment is terminated, but Grantee declines an offer of employment involving a loss of compensation of less than 15% from a purchaser, transferee,
outsourced vendor, new operating entity or affiliated employer; (ii) a substantial diminution in Grantee’s title, duties and responsibilities, other than any isolated, insubstantial and inadvertent failure by the Company that is not in bad
faith and is cured within ten (10) business days after Grantee gives the Company written notice of such event; or (iii) a transfer of Grantee’s primary workplace to a location that is more than twenty (20) miles from his or her
workplace as of the date of this Agreement; provided that Good Reason shall not be deemed to occur merely because Grantee’s willful decision to change position or status within the Company causes one or more of the occurrences described
in (i), (ii), or (iii) to come about. 
 Section 1.3.    Permanent Disability 

“Permanent Disability” shall mean “Disability” as such term is defined in any employment agreement between
Grantee and the Company, or, if there is no such employment agreement, “Disability” as defined in the long-term disability plan of the Company applicable to Grantee or that would apply to the Grantee if the Grantee were
employed with the Company at the applicable time. 
 Section 1.4.    Retirement 

“Retirement” shall mean Grantee’s resignation from service with the Company (i) after attaining 65 years of
age or (ii) after attaining 60 years of age and completing twenty (20) years of service with the Company. 

Section 1.5.    SARs 

“SARs” shall mean the aggregate number of SARs granted under Section 2.1 of this Agreement.

 Section 1.6.    Secretary 

“Secretary” shall mean the Secretary of the Company. 

ARTICLE II 
 GRANT OF SARS

 Section 2.1.    Grant of SARs 

For good and valuable consideration, on and as of the date hereof the Company grants to the Grantee an award of SARs (the
“Award”) on the terms 

  
 3 

 
and conditions set forth in this Agreement. Each SAR represents the right to receive pursuant to this Agreement, upon exercise of the SAR, a payment from the Company in shares of Common Stock
having a value equal to the excess of the Fair Market Value of one Share on the exercise date over the Base Price (as defined below). 

Section 2.2.    Base Price 

Subject to Section 2.4, the base price of each SAR granted pursuant to this Agreement (the
“Base Price”) shall be as set forth on the first page of this Agreement. 
 Section 2.3.    No Guarantee of
Employment 
 Nothing in this Agreement or in the Plan shall confer upon the Grantee any right to continue in the
employ of the Company nor interfere with or restrict in any way the rights of the Company, which are hereby expressly reserved, to terminate the employment of the Grantee at any time for any reason whatsoever, with or without cause, subject to the
applicable provisions of, if any, the Grantee’s employment agreement with the Company or offer letter provided by the Company to the Grantee. 

Section 2.4.    Adjustments to SARs 

The SARs shall be subject to the adjustment provisions of Sections 8 and 9 of the Plan, provided, however, that
in the event of the payment of an extraordinary dividend by the Company to its stockholders, then: first, the Base Price of each SAR shall be reduced by the amount of the dividend per share paid, but only to the extent the Committee
determines it to be permitted under applicable tax laws and it will not have adverse tax consequences to the Grantee; and, if such reduction cannot be fully effected due to such tax laws, second, the Company shall pay to the Grantee a cash
payment, on a per SAR basis, equal to the balance of the amount of the dividend not permitted to be applied to reduce the Base Price of the applicable SARs as follows: (a) for each Share with respect to which a vested SAR relates, promptly
following the date of such dividend payment; and (b), for each Share with respect to which an unvested SAR relates, on the date on which such SAR becomes vested and exercisable with respect to such Share. 

ARTICLE III 
 PERIOD OF
EXERCISABILITY 
 Section 3.1.    Commencement of Exercisability 

(a) So long as the Grantee continues to be employed by the 

  
 4 

 
Company, this Award shall become vested and exercisable with respect to 25% of the SARs on each of the first four anniversaries of the Grant Date (each such date, a “Vesting
Date”). Except as provided in Section 3.1(b), or as otherwise provided by the Committee, no part of this Award shall become vested as to any additional SARs as of any date following the termination of
Grantee’s employment with the Company for any reason and any SAR, which is (or determined to be) unvested as of the Grantee’s termination of employment, shall immediately expire without payment therefor. 

(b)    Notwithstanding the foregoing, any unvested SARs may become vested prior to the applicable Vesting
Date, or continue to vest (and not be forfeited) following Grantee’s termination of employment, under the following circumstances: 

(1)    Upon the occurrence of a Change in Control (the definition of which is set forth on Schedule
A attached hereto): 
 (A)    In the event the entity surviving the Change in Control (the
“Successor”) assumes the Award granted hereby, if the Grantee’s employment with the Successor is terminated without Cause by the Successor, or terminates for Good Reason by the Grantee or on account of Grantee’s death,
Permanent Disability, or Retirement prior to an applicable Vesting Date, all unvested SARs not previously forfeited shall immediately vest and become exercisable as of the date of such termination of employment for the applicable period set forth in
Section 3.2; 
 (B)    In the event the Successor does not assume the Award
granted hereby, all SARs not previously forfeited shall vest (if not already vested) immediately prior to the effective date of the Change in Control, and shall be cancelled in exchange for the payment described in Section 9(a)(ii)(A) of the
Plan as of the effective date of the Change in Control; 
 (2)    Upon the Grantee’s Retirement on
or after the first anniversary of the Grant Date, except as otherwise provided by Section 3.1(b)(1), any unvested SARs shall immediately thereupon vest and shall not be forfeited, but shall become exercisable only at the
time such SARs would have become exercisable in accordance with Section 3(a) or this Section 3(b) had the Grantee remained employed with the Company through each applicable Vesting Date or
Grantee’s earlier death or Permanent Disability; for the avoidance of doubt, in the event of Grantee’s Retirement prior to such one year anniversary of the Grant Date, unless otherwise provided in
Section 3.1(b)(1)(A), no part of this Award shall become vested and all SARs subject to this Award shall immediately expire without payment therefor; 

(3)    In the event of the Grantee’s termination of employment on account of Grantee’s death or
Permanent Disability on or after the first anniversary of the Grant Date, all unexercised SARs not previously forfeited shall vest and become exercisable immediately upon such termination. 

  
 5 

 Section 3.2.    Expiration of SARs 

The Grantee may not exercise any SAR granted pursuant to this Award, and any unexercised SAR shall immediately expire without
any payment therefor, after the first to occur of the following events: 
 (a)    The tenth anniversary
of the Grant Date so long as the Grantee remains employed with the Company or a Successor through such date; 

(b)    The fourth anniversary of the date of the Grantee’s termination of employment with the Company
or a Successor, if the Grantee’s employment terminates by reason of death or Permanent Disability; 

(c)    Immediately upon the date of the Grantee’s termination of employment by the Company or a
Successor for Cause; 
 (d)    One hundred and eighty (180) days after the date of the
Grantee’s termination of employment by the Company or a Successor without Cause (for any reason other than as set forth in Section 3.2(b)); 

(e)    One hundred and eighty (180) days after the date of the Grantee’s termination of
employment with the Company or a Successor by the Grantee for Good Reason; 
 (f)    The fourth
anniversary of the date of the Grantee’s termination of employment with the Company or a Successor by the Grantee upon Retirement; or 

(g)    Sixty (60) days after the date of the Grantee’s termination of employment with the
Company or a Successor by the Grantee without Good Reason (except due to Retirement, death or Permanent Disability). 
 For the avoidance of
doubt, for purposes of this Agreement, Grantee’s employment shall not be deemed to have terminated so long as Grantee remains employed by any Service Recipient. 

ARTICLE IV 
 EXERCISE 

Section 4.1.    Person Eligible to Exercise 

The Grantee may exercise only that portion of this Award that has both vested and become exercisable at the time Grantee
desires to exercise this Award and that has not expired pursuant to Section 3.2. During the lifetime of the 

  
 6 

 
Grantee, only the Grantee (or his or her duly authorized legal representative) may exercise the SARs granted pursuant to this Award or any portion thereof. After the death of the Grantee, any
vested and exercisable portion of this Award may, prior to the time when such portion becomes unexercisable under Section 3.2, be exercised by his personal representative or by any person empowered to do so under the
Grantee’s will or under the then applicable laws of descent and distribution. 
 Section 4.2.    Partial Exercise

 Any vested and exercisable portion of this Award, or the entire Award, if then wholly vested and exercisable, may be
exercised in whole or in part at any time prior to the time when the Award or portion thereof becomes unexercisable under Section 3.2. 

Section 4.3.    Manner of Exercise 

Subject to the Company’s code of conduct and securities trading policies as in effect from time to time, this Award, or
any exercisable portion thereof, may be exercised solely by delivering to the Company or its designated agent all of the following prior to the time when the Award or such portion expires under Section 3.2: 

(a)    Notice in writing (or such other medium acceptable to the Company or its designated agent) signed
or acknowledged by the Grantee or other person then entitled to exercise the Award, stating the number of SARs subject to the Award in respect of which the Award is thereby being exercised, such notice complying with all applicable rules established
by the Committee; 
 (b)    (i) Full payment (in cash or by check or by a combination thereof) to
satisfy the minimum withholding tax obligation with respect to which the Award or portion thereof is exercised or (ii) indication that the Grantee elects to satisfy the withholding tax obligation through an arrangement that is compliant with
the Sarbanes-Oxley Act of 2002 (and any other applicable laws and exchange rules) and that provides for the delivery of irrevocable instructions to a broker to sell Shares obtained upon the exercise of the Award and to deliver promptly to the
Company an amount to satisfy the minimum withholding tax obligation that would otherwise be required to be paid by the Grantee to the Company pursuant to clause (i) of this subsection (b), or (iii) if made available by the Company,
indication that the Grantee elects to have the number of Shares that would otherwise be issued to the Grantee upon exercise of such Award (or portion thereof) reduced by a number of Shares having an aggregate Fair Market Value, on the date of such
exercise, equal to the payment to satisfy the minimum withholding tax obligation that would otherwise be required to be made by the Grantee to the Company pursuant to clause (i) of this subsection (b). 

(c)    If required by the Company, a bona fide written 

  
 7 

 
representation and agreement, in a form satisfactory to the Company, signed by the Grantee or other person then entitled to exercise such Award or portion thereof, stating that the shares of
Common Stock are being acquired for his own account, for investment and without any present intention of distributing or reselling said shares or any of them except as may be permitted under the Securities Act of 1933, as amended (the
“Act”), and then applicable rules and regulations thereunder, and that the Grantee or other person then entitled to exercise such Award or portion thereof will indemnify the Company against and hold it free and harmless from any
loss, damage, expense or liability resulting to the Company if any sale or distribution of the shares by such person is contrary to the representation and agreement referred to above; provided, however, that the Company may, in its reasonable
discretion, take whatever additional actions it deems reasonably necessary to ensure the observance and performance of such representation and agreement and to effect compliance with the Act and any other federal or state securities laws or
regulations; and 
 (d)    In the event the Award or portion thereof shall be exercised pursuant to
Section 4.1 by any person or persons other than the Grantee, appropriate proof of the right of such person or persons to exercise the Award. 

Without limiting the generality of the foregoing, the Company may require an opinion of counsel acceptable to it to the effect that any
subsequent transfer of shares acquired on exercise of this Award (or portion thereof) does not violate the Act, and may issue stop-transfer orders covering such Shares. Share certificates evidencing stock issued on exercise of any portion of this
Award shall bear an appropriate legend referring to the provisions of subsection (c) above and the agreements herein. The written representation and agreement referred to in subsection (c) above shall, however, not be required if the
shares to be issued pursuant to such exercise have been registered under the Act, and such registration is then effective in respect of such shares. 

Section 4.4.    Conditions to Issuance of Stock Certificates 

The Shares issuable (whether by certificate or otherwise) upon the exercise of this Award, or any portion thereof, may be
either previously authorized but unissued Shares or issued Shares, which have then been reacquired by the Company. Such Shares shall be fully paid and nonassessable. If share certificates are to be issued, the Company shall not be required to issue
or deliver any certificate or certificates for Shares purchased upon the exercise of this Award or portion thereof prior to fulfillment of all of the following conditions: 

(a)    The obtaining of approval or other clearance from any state or federal governmental agency which
the Committee shall, in its reasonable and good faith discretion, determine to be necessary or advisable; and 

(b)    The lapse of such reasonable period of time following the exercise of the Award as the Committee
may from time to time establish for reasons of administrative convenience or as may otherwise be required by applicable law. 

  
 8 

 Section 4.5.    Rights as Stockholder 

Except as otherwise provided in Section 2.4 of this Agreement, the holder of any SARs subject to this
Award shall not be, nor have any of the rights or privileges of, a stockholder of the Company in respect of any Shares issuable upon the exercise of this Award or any portion thereof unless and until certificates representing such Shares shall have
been issued by the Company to such holder, or the Company or its designated agent has otherwise recorded the appropriate book entries evidencing Grantee’s ownership of the Shares. 

ARTICLE V 
 MISCELLANEOUS

 Section 5.1.    Administration 

The Committee shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration,
interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules. All actions taken and all interpretations and determinations made by the Committee shall be final and binding upon the Grantee, the
Company and all other interested persons. No member of the Committee shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Award. In its absolute discretion, the Board may at
any time and from time to time exercise any and all rights and duties of the Committee under the Plan and this Agreement. 

Section 5.2.    Award Not Transferable 

No part of, or interest in, this Award shall be liable for the debts, contracts or engagements of the Grantee or his successors
in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment,
garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect; provided, however, that this Section 5.2 shall not prevent
transfers by will or by the applicable laws of descent and distribution. 
 Section 5.3.    Notices 

Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of its
Secretary or its designee, and any notice to be given to the Grantee shall be addressed to him at 

  
 9 

 
the address (including an electronic address) reflected in the Company’s books and records. By a notice given pursuant to this Section 5.3, either party may
hereafter designate a different address for notices to be given to him. Any notice, which is required to be given to the Grantee, shall, if the Grantee is then deceased, be given to the Grantee’s personal representative if such representative
has previously informed the Company of his status and address by written notice under this Section 5.3. Any notice shall have been deemed duly given when (i) delivered in person, (ii) delivered in an electronic
form approved by the Company, (iii) enclosed in a properly sealed envelope or wrapper addressed as aforesaid, deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service, or
(iv) enclosed in a properly sealed envelope or wrapper addressed as aforesaid, deposited (with fees prepaid) in an office regularly maintained by FedEx, UPS, or comparable non-public mail carrier. 

Section 5.4.    Titles; Pronouns 

Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this
Agreement. The masculine pronoun shall include the feminine and neuter, and the singular the plural, where the context so indicates. 

Section 5.5.    Applicability of Plan  

The Grantee hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all the terms and provisions thereof.
The terms of this Agreement are governed by the terms of the Plan, and in the case of any inconsistency between the terms of this Agreement and the terms of the Plan, the terms of the Plan shall govern. 

Section 5.6.    Amendment 

Subject to Section 10 of the Plan, this Agreement may be amended only by a writing executed by the parties hereto, which
specifically states that it is amending this Agreement. 
 Section 5.7    Governing Law 

The laws of the State of Delaware shall govern the interpretation, validity and performance of the terms of this Agreement
regardless of the law that might be applied under principles of conflicts of laws. 
 Section 5.8    Arbitration 

In the event of any controversy among the parties hereto arising out of, or relating to, this Agreement which cannot be settled
amicably by the parties, 

  
 10 

 
such controversy shall be finally, exclusively and conclusively settled by mandatory arbitration conducted expeditiously in accordance with the American Arbitration Association rules, by a single
independent arbitrator. Such arbitration process shall take place within the Nashville, Tennessee metropolitan area. The decision of the arbitrator shall be final and binding upon all parties hereto and shall be rendered pursuant to a written
decision, which contains a detailed recital of the arbitrator’s reasoning. Judgment upon the award rendered may be entered in any court having jurisdiction thereof. Each party shall bear its own legal fees and expenses, unless otherwise
determined by the arbitrator. If the Grantee substantially prevails on any of his or her substantive legal claims, then the Company shall reimburse all legal fees and arbitration fees incurred by the Grantee to arbitrate the dispute. 

IN WITNESS WHEREOF, this Agreement has been executed and delivered by the parties hereto. 

 

			
	 HCA HEALTHCARE, INC.

 
			
		
	 By:
	 	 
		
	 Its:
	 	 

 
			
	
	 Grantee:

	
	 (electronically accepted)

  
 11 

 Schedule A 

Definition of Change in Control 

For purposes of this Agreement, the term “Change in Control” shall mean, in lieu of any definition contained in the Plan: 

(i)     the sale or disposition, in one or a series of related transactions, of all or substantially all
of the assets of the Company to any Person or Group other than an employee benefit plan (or trust forming a part thereof) maintained by (1) the Company or (2) any corporation or other Person of which a majority of its voting power of its
voting equity securities or equity interest is owned, directly or indirectly, by the Company (a “Permitted Holder”); or 

(ii)    any Person or Group, other than a Permitted Holder, becomes the Beneficial Owner (as such term is
defined in Rule 13d-3 under the Exchange Act (or any successor rule thereto) (except that a Person shall be deemed to have “beneficial ownership” of all shares that any such Person has the right to
acquire, whether such right is exercisable immediately or only after the passage of time)), directly or indirectly, of more than 50% of the total voting power of the voting stock of the Company (or any entity which controls the Company), including
by way of merger, consolidation, tender or exchange offer or otherwise; or 
 (iii)    a reorganization,
recapitalization, merger or consolidation (a “Corporate Transaction”) involving the Company, unless securities representing more than 50% of the combined voting power of the then outstanding voting securities entitled to vote generally in
the election of directors of the Company or the corporation resulting from such Corporate Transaction (or the parent of such corporation) are Beneficially Owned subsequent to such transaction by the Person or Persons who were the Beneficial Owners
of the outstanding voting securities entitled to vote generally in the election of directors of the Company immediately prior to such Corporate Transaction, in substantially the same proportions as their ownership immediately prior to such Corporate
Transaction; or 
 (iv)    during any period of 12 months, individuals who at the beginning of such
period constituted the Board (together with any new directors whose election by such Board or whose nomination for election by the shareholders of the Company was approved by a vote of a majority of the directors of the Company, then still in
office, who were either directors at the beginning of such period or whose election or nomination for election was previously so approved) cease for any reason to constitute a majority of the Board then in office.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]